1stOncology™: Cancer Intelligence Service – Page 14442 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Esanex to Present Data at the 2018 American Association for Cancer Research (AACR) Annual Meeting

On April 3, 2018 Esanex, Inc., a clinical stage company developing Heat Shock Protein inhibitors for the treatment of cancer, reported that it will present data at the 2018 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting taking place in Chicago from April 14 – April 18 (Press release, Esanex, APR 3, 2018, View Source [SID1234525168]). Data on Esanex’s pre-clinical studies of SNX-2112, the active form of SNX-5422, will be presented in a poster in the Experimental and Molecular Therapeutics track, in session PO.IM02.03 – Immune Mechanisms Invoked by Therapies 1.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Poster Presentation Details:

Title: Transcriptomics analysis of SNX-2112 on immune and mitochondrial genes
Abstract No: 2758
Poster Board Number: 20
Date/Time: Monday, Apr 16, 2018 1:00 PM – 5:00 PM
Location: McCormick Place South, Exhibit Hall A, Poster Section 33

About SNX-5422
SNX-5422 is a chemically unique, orally active Hsp90 inhibitor that has provided durable clinical responses in open label trials in non-small cell lung cancer (NSCLC) and neuroendocrine tumors (NET). The potential of SNX-5422 in hematologic cancers is currently being explored in a chronic lymphocytic leukemia (CLL) open label clinical trial (clinicaltrials.gov ID#NCT02973399). With approximately 200 patients treated to date, SNX-5422 has a well-established safety profile that supports studying it in combination with existing approved drugs in a variety of clinical settings.

argenx to present complete data from the Phase 2 clinical trial of efgartigimod (ARGX-113) in myasthenia gravis at the American Academy of Neurology Annual Meeting

On April 3, 2018 argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, reported that it will present complete data from the Phase 2 clinical trial of efgartigimod (ARGX-113) in myasthenia gravis at the 2018 American Academy of Neurology (AAN) Annual Meeting in Los Angeles, CA (Press release, argenx, APR 3, 2018, http://www.argenx.com/en-GB/news-internal/argenx-to-present-complete-data-from-the-phase-2-clinical-trial-of-efgartigimod-argx-113-in-myasthenia-gravis-at-the-american-academy-of-neurology-annual-meeting/30178/ [SID1234525166]).

Details on the presentation are as follows:

Date & Time: Tuesday, April 24, 2018, 9:15 a.m. – 11:30 a.m. PT

Presentation Title: A double-blind placebo-controlled study to evaluate the safety and efficacy of
FcRn-antagonist efgartigimod (ARGX-113) in generalized myasthenia gravis

Investor Event and Webcast Information

argenx will host an investor event on Tuesday, April 24, 2018, beginning at 1:00 p.m. PT in Los Angeles to discuss the complete efgartigimod clinical data presented at AAN earlier that day. The event will be webcast live and can be accessed on the argenx website www.argenx.com or by clicking here.

About efgartigimod

Efgartigimod (ARGX-113) is an investigational therapy for IgG-mediated autoimmune diseases and was designed to exploit the natural interaction between IgG antibodies and the recycling receptor FcRn. ARGX-113 is the Fc-portion of an antibody that has been modified by the argenx proprietary ABDEG technology to increase its affinity for FcRn beyond that of normal IgG antibodies. As a result, ARGX-113 blocks antibody recycling through FcRn binding and leads to fast depletion of the autoimmune disease-causing IgG autoantibodies. The development work on ARGX-113 is done in close collaboration with Prof. E. Sally Ward (University of Texas Southwestern Medical and Texas A&M University Health Science Center, a part of Texas A&M University (TAMHSC)).

Reata to Present Preclinical Data on RTA 1701, a Novel ROR?t Inverse Agonist, at Upcoming Immunology Conference

On April 3, 2018 Reata Pharmaceuticals, Inc. (Nasdaq:RETA) (Reata or Company), a clinical-stage biopharmaceutical company, reported the upcoming presentation of preclinical data for its novel RORγt inverse agonist RTA 1701 at the Annual Meeting of the American Association of Immunologists in Austin, Texas on May 6-7, 2018 (Press release, Reata Pharmaceuticals, APR 3, 2018, View Source;p=RssLanding&cat=news&id=2340738 [SID1234525163]). RTA 1701 is the lead product candidate from Reata’s proprietary series of RORγt inverse agonists for the potential treatment of a broad range of autoimmune, inflammatory, and fibrotic diseases. RTA 1701 is an orally-bioavailable, RORγt-selective, inverse agonist that demonstrates strong efficacy in rodent disease models. RTA 1701 potently suppresses production of IL-17A, a clinically important cytokine, in human immune cells and when dosed orally to non-human primates.

Reata will present key preclinical data characterizing RTA 1701 in the following sessions:

Dulubova et al., "RTA 1701 is an orally-bioavailable, potent, and selective RORγt inhibitor that suppresses Th17 differentiation in vitro and is efficacious in mouse models of autoimmune disease." May 6, 2:30 pm CT.
Reisman et al., "RTA 1701 is an oral RORγt inhibitor that suppresses the IL-17A response in non-human primates." May 7, 2:30 pm CT.
"Our data with RTA 1701, and especially our primate proof-of-concept experiments, are highly encouraging," said Keith Ward, Ph.D., Reata’s Chief Development Officer. "We believe that a high, unmet need remains for patients with autoimmune and inflammatory disorders, and that RTA 1701 represents a promising small molecule development candidate in these indications." RTA 1701 was discovered by Reata, who holds global rights for the asset.

Reata plans to continue the development of RTA 1701 with a first-in-human study in 2018 that includes evaluation of IL-17A suppression with initial results expected by 1H19.

About RORγt

RORγt is the key transcription factor that orchestrates the differentiation of Th17 cells and drives production of key pro-inflammatory cytokines, including IL-17A. Aberrant IL-17A signaling has been implicated in many diseases, including chronic inflammatory and autoimmune diseases such as rheumatoid arthritis, psoriasis, inflammatory bowel disease, multiple sclerosis, and many others. Therefore, suppression of activity of RORγt via an inverse agonist such as RTA 1701 has the potential for broad activity across multiple therapeutic areas of high, unmet medical need.

PDL BioPharma to Present at the H.C. Wainwright Global Life Sciences Conference

On April 3, 2018 PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) reported that Peter Garcia, PDL’s vice president and chief financial officer, will present at the H.C. Wainwright Global Life Sciences Conference next week in Monaco (Press release, PDL BioPharma, APR 3, 2018, View Source [SID1234525162]). The session will be webcast live and will occur on Tuesday, April 10, 2018 at 1:45 p.m. CEST.

To access the live and subsequently archived webcast of the presentation, go to the company’s website at View Source and go to "Presentations and Events." Please connect to the website at least 15 minutes prior to the presentation to allow for any software download that may be necessary. The archived webcast will be available for at least seven days following the presentation.

OncoSec to Host Research Reception During the 2018 American Association of Cancer Research Annual Meeting

On April 3, 2018 OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, reported it will host a Research Reception at the 2018 American Association of Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting (Press release, OncoSec Medical, APR 3, 2018, View Source [SID1234525161]). The reception, for which registration is required, will be held on Sunday, April 15, 2018 at 6:00 p.m. CT at the JW Marriott in Chicago, IL.

The OncoSec Research Reception will feature the following presentations:

OMS-140 Protocol; Review of Intratumoral IL-12 Data in TNBC Presented at AACR (Free AACR Whitepaper)
Pamela Munster, MD, UCSF Helen Diller Family Comprehensive Cancer Center
OMS-141 Protocol; Upcoming PD-1 Combination Clinical Trial in TNBC
Melinda Telli, MD, Stanford University Medical Center
Melanoma Data Update: OMS-100 & OMS-102 Combination Study
Alain Algazi, MD, UCSF Helen Diller Family Comprehensive Cancer Center
PISCES/KEYNOTE-695 Operational Update
Sharron Gargosky, PhD, Chief Clinical and Regulatory Officer, OncoSec
Attendees will also have the opportunity to view the TNBC data featured as an oral poster at AACR (Free AACR Whitepaper) and ask questions of the lead author. All speakers will be available for questions. Space is limited. For those interested in attending this event in person, please contact [email protected].

An archived version of the presentation will be available for 90 days on OncoSec’s website: www.oncosec.com.